Figures & data
Table 1 Median duration of disease and duration of LAI treatment (months) depending on components of metabolic syndrome – cardiovascular risk factors
Table 2 Median duration of disease and duration of treatment with LAI (months) according to echocardiography parameters
Table 3 Comparison of echocardiographic parameters between olanzapine and risperidone (Mann–Whitney U test results)